Larimar Therapeutics, Inc.
LRMR
$4.36
-$0.19-4.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.26M | 18.75M | 17.91M | 16.97M | 16.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.54M | 105.34M | 90.89M | 73.76M | 65.83M |
| Operating Income | -108.54M | -105.34M | -90.89M | -73.76M | -65.83M |
| Income Before Tax | -99.79M | -95.23M | -80.60M | -64.77M | -58.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.79 | -95.23 | -80.60 | -64.77 | -58.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.79M | -95.23M | -80.60M | -64.77M | -58.34M |
| EBIT | -108.54M | -105.34M | -90.89M | -73.76M | -65.83M |
| EBITDA | -108.21M | -105.02M | -90.57M | -73.44M | -65.51M |
| EPS Basic | -1.56 | -1.49 | -1.31 | -1.15 | -1.12 |
| Normalized Basic EPS | -0.98 | -0.93 | -0.82 | -0.72 | -0.70 |
| EPS Diluted | -1.56 | -1.49 | -1.31 | -1.15 | -1.12 |
| Normalized Diluted EPS | -0.98 | -0.93 | -0.82 | -0.72 | -0.70 |
| Average Basic Shares Outstanding | 255.61M | 255.38M | 244.97M | 225.07M | 205.17M |
| Average Diluted Shares Outstanding | 255.61M | 255.38M | 244.97M | 225.07M | 205.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |